Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey SAGE Palliative Medicine & Chronic Care

This episode features Sue-Ling Chang, (CHU de Québec-Université Laval Research Center, Oncology Division, Québec City, QC, Canada)
 
What is already known about the topic?
There is a growing interest in psilocybin-assisted therapy worldwide, particularly to treat existential distress at the end of life.  
What this paper adds?
In this study, we show that the social acceptability of psilocybin-assisted therapy to treat existential distress at the end of life is high in Canada and identify factors associated with favourable attitudes of the population towards it.  
Implications for practice, theory, or policy
Our findings may help mobilise resources to address barriers and challenges for implementing psilocybin-assisted therapy within palliative medicine and society. This could also have implications for policies regarding medical assistance in dying.  Full paper available from:    
https://journals.sagepub.com/doi/full/10.1177/02692163231222430
 If you would like to record a podcast about your published (or accepted) Palliative Medicine paper, please contact Dr Amara Nwosu: 
a.nwosu@lancaster.ac.uk